Safety profile of novel amodipine salts to be elucidated, Pfizer Korea says

Published: 2004-06-14 07:00:00

Updated: 2004-06-14 07:00:00

Amid hectic rush of Korean pharmaceutical makers to develop novel amodipine salts, Pfizer Korea expressed its concerns over their safety and efficacy, as the chemical structures of these salts are different from that of Norvasc (amlodipine besylate), the world's best-selling prescription drug in ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK